Cases
Juno Therapeutics, Inc. (NASDAQ: JUNO)
Securities Class Action
Overview
Overview
- Date:
- 7/12/2016
- Company Name:
- Juno Therapeutics, Inc.
- Stock Symbol:
- JUNO
- Class Period:
- FROM 5/9/2016 TO 7/7/2016
- Status:
- Closed/Complete
- Court:
- U.S. District Court: Disrtict of Western Washington
NEW YORK, July 12, 2016 – Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the Western District of Washington on behalf of all persons or entities who acquired Juno Therapeutics, Inc. (NASDAQ: JUNO) securities between May 9, 2016 and July 7, 2016 (the “Class Period”).
Juno is a biopharmaceutical company that engages in the development of cell-based cancer immunotherapies. The company specializes in its chimeric antigen receptor and T cell receptor technologies that are designed to genetically engineer T cells to recognize and kill cancer cells.
On July 7, 2016, post-market, Juno disclosed that three patients had passed away during a clinical trial for the company's chemotherapy drug, fludarabine.
On this news, Juno's share price fell over 30% to just $27.50 on July 8, 2016.
If you acquired Juno securities during the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
Juno is a biopharmaceutical company that engages in the development of cell-based cancer immunotherapies. The company specializes in its chimeric antigen receptor and T cell receptor technologies that are designed to genetically engineer T cells to recognize and kill cancer cells.
On July 7, 2016, post-market, Juno disclosed that three patients had passed away during a clinical trial for the company's chemotherapy drug, fludarabine.
On this news, Juno's share price fell over 30% to just $27.50 on July 8, 2016.
If you acquired Juno securities during the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.